GIC Pte. Ltd. is a sovereign wealth fund wholly owned by the Government of Singapore, established in 1981 to manage the country’s foreign reserves. The firm focuses on securing Singapore's financial future by investing across a diverse range of asset classes in both public and private markets. Its investment strategy includes public and private equity, with particular emphasis on health care, financial services, natural resources, real estate, and fixed income, as well as alternative markets such as foreign exchange and commodities. GIC also engages in venture capital, providing seed capital to start-ups and growth companies. The organization operates through subsidiaries that specialize in various investment categories and maintains a global presence with offices in key financial centers around the world. GIC aims to achieve sustainable long-term returns above global inflation, thereby fulfilling its responsibility to preserve and enhance Singapore's financial reserves for future generations.
Max Healthcare Institute Ltd is a prominent healthcare service provider in India, offering a comprehensive range of medical services. The organization operates hospitals equipped with outpatient, day care, emergency, and inpatient departments, catering to various medical specialties including orthopedics, internal medicine, general surgery, cardiac sciences, oncology, neurosciences, and obstetrics. Additionally, Max Healthcare collaborates with third-party healthcare providers through long-term service contracts for clinical, radiology, and pathology services. This integrated approach enables the organization to deliver quality healthcare and diagnostics across its facilities, ensuring a wide reach in the Indian healthcare market.
Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation.
The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.
Asia Healthcare Holdings(AHH)
Secondary Market in 2022
Asia Healthcare Holdings is an operating and investment platform founded by TPG Growth.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Metro Pacific Hospital Holdings is the largest private hospital operator in the Philippines. It has a nationwide portfolio of 14 hospital, supported by 2 allied health colleges, a growing network of primary care of clinics and cancer care centers and a central clinical laboratory.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.